CN109106714B

CN109106714B - Pharmaceutical composition for relieving cough, reducing sputum and relieving asthma and preparation thereof

Info

Publication number: CN109106714B
Application number: CN201810847965.2A
Authority: CN
Inventors: 焦豪妍; 汤庆发; 郑海; 沈小钟; 邱蔚芬; 崔穗旭
Original assignee: Guangdong Food and Drugs Vocational College
Current assignee: Guangdong Food and Drugs Vocational College
Priority date: 2018-07-27
Filing date: 2018-07-27
Publication date: 2021-02-05
Anticipated expiration: 2038-07-27
Also published as: CN109106714A

Abstract

The invention relates to a pharmaceutical composition for relieving cough, reducing sputum and relieving asthma, which comprises behcet and quercetin. A large number of researches show that the bevacizine and the quercetin have synergistic effect, and the pharmaceutical composition formed by combining the bevacizine and the quercetin has good effects of relieving cough, reducing phlegm and relieving asthma. Moreover, the proper dosage proportion is further adopted, and the synergistic effect of the two is very good.

Description

Pharmaceutical composition for relieving cough, reducing sputum and relieving asthma and preparation thereof

Technical Field

The invention belongs to the field of medicines, and relates to a pharmaceutical composition for relieving cough, reducing phlegm and relieving asthma and a preparation thereof.

Background

The sipeline is an important alkaloid contained in Fritillaria pallidiflora (Fritillaria unibracteata) and can be used together with monomeric alkaloids in Fritillaria cirrhosa to prepare antitussive, expectorant and/or antiinflammatory medicine.

Quercetin, also known as quercetin, is soluble in glacial acetic acid, and the alkaline aqueous solution is yellow and almost insoluble in water, and the ethanol solution is bitter in taste. Can be used as a medicine, some reports suggest that the medicine has the functions of eliminating phlegm and relieving cough and has certain effect of relieving asthma, and the medicine can also be used for treating chronic bronchitis.

Cough and expectoration are two common symptoms of respiratory diseases, are closely related in pathology, and generally cough often contains phlegm, and the cough often causes cough, and emphysema, bronchiectasis, pulmonary heart disease and the like can be caused after long-term unhealing.

At present, the most widely used antitussives in pharmaceutical drugs include codeine phosphate and dextromethorphan hydrobromide.

Codeine phosphate is a central nervous system chemical widely used for cough or cold, but the management level is increased by national food and drug supervision and management again and again in recent years due to serious adverse reactions. The common adverse reactions are as follows: psycho-metamorphosis or fantasy; weak, slow or irregular breathing; heart rate is either fast or slow, abnormal. Rare adverse reactions: convulsions, tinnitus, tremors or involuntary muscle movements, etc.; urticaria; allergic reactions such as rash itching, rash or swelling of the face; mental depression and muscle rigidity, etc. Long-term use can cause dependency. The tendency of the conventional dose to cause dependence is weaker than that of other morphine-type drugs. Typical symptoms are: chicken dermatoma, anorexia, diarrhea, toothache, nausea, emesis, watery nasal discharge, shivering, sneezing, yawn, sleep disorder, stomach spasm, hyperhidrosis, asthenia, increased heart rate, and emotional arousal or fever of unknown reason.

Dextromethorphan hydrobromide is also a commonly used central nervous system antitussive and is available to consumers in pharmacies. However, serious adverse reactions, particularly abuse, occur along with the increase of the dosage, and the death of patients caused by overdosing of capsules packaged by the powdered dextromethorphan is reported many times abroad. The U.S. food and drug administration is constantly concerned about the abuse of dextromethorphan and issues warnings not to abuse dextromethorphan. The U.S. food and drug administration has shown that small doses of dextromethorphan, when used correctly, can safely and effectively suppress cold symptoms, but abuse can cause death and other serious adverse effects, such as brain damage, seizures, loss of consciousness, and irregular heartbeat.

Therefore, the search for safe, effective and low-side-effect cough-relieving, phlegm-eliminating and asthma-relieving medicines is a very valuable research approach.

Disclosure of Invention

One of the purposes of the invention is to provide a pharmaceutical composition for relieving cough, eliminating phlegm and relieving asthma with good curative effect and small side effect.

The technical scheme for achieving the purpose is as follows.

A pharmaceutical composition for relieving cough, eliminating phlegm and relieving asthma contains active ingredients of bevacizine and quercetin.

In one embodiment, the mass ratio of the bevacizine to the quercetin is as follows: 5-50: 20 to 200 parts.

In one embodiment, the mass ratio of the bevacizine to the quercetin is as follows: (25 ± 2): (100. + -.2).

In one embodiment, the mass ratio of the bevacizine to the quercetin is as follows: 25: 100.

the invention also aims to provide the application of the pharmaceutical composition in preparing the medicaments for relieving cough, eliminating phlegm and relieving asthma.

Another object of the present invention is to provide a pharmaceutical preparation for relieving cough, eliminating phlegm and relieving asthma.

The technical scheme for achieving the purpose is as follows.

A pharmaceutical preparation for relieving cough, eliminating phlegm and relieving asthma comprises the pharmaceutical composition for relieving cough, eliminating phlegm and relieving asthma and pharmaceutically acceptable auxiliary materials.

The dosage form of the pharmaceutical preparation is tablets, capsules, granules, pills and microspheres.

The pharmaceutically acceptable auxiliary materials comprise starch, lactose, mannitol, calcium hydrogen phosphate, carboxymethyl starch or salts and group substitutes thereof, dextrin, chitosan, polyvinylpyrrolidone, celluloses and derivatives thereof, and polyethylene glycols, wherein the starch is starch, tapioca starch, soluble starch, pregelatinized starch; the cellulose can be methylcellulose, ethyl cellulose, hydroxypropyl methylcellulose, and microcrystalline cellulose; the polyethylene glycol is 200-20000.

Through a large number of researches, the invention discovers that the bevacizine and the quercetin have synergistic effect, and the pharmaceutical composition formed by creatively combining the bevacizine and the quercetin has good functions of relieving cough, reducing phlegm and relieving asthma. Moreover, the proper dosage proportion is further adopted, and the synergistic effect of the two is very good.

The pharmaceutical composition can be used for treating cough, expectoration and asthma, does not cause the side effects of lethargy, nausea and vomiting when being taken, can be added with conventional auxiliary materials and can be prepared into the drugs for relieving cough, eliminating phlegm and relieving asthma according to any conventional method.

Drawings

Fig. 1 is an effect-combination index curve of sibiricin and quercetin.

Detailed Description

The present invention will be further described with reference to the following examples.

Example 1:

taking 25g of the sibiricin and 100g of the quercetin. Firstly, adding 25g of the sipeimine into 30g of the starch, uniformly mixing, then uniformly mixing with 100g of the quercetin, then adding 2g of the micro-powder silica gel, uniformly mixing, and filling into 1000 capsules to obtain the capsules.

Example 2:

taking 25g of the sipeimine and 100g of the quercetin, adding 30g of the starch, mixing uniformly, adding 2g of the micro-powder silica gel, mixing uniformly, and filling into 1000 capsules to obtain the capsules.

Example 3:

taking 25g of the sibiricin and 100g of the quercetin. Firstly, 100g of quercetin is added with 130g of starch and mixed evenly, then the mixture is mixed with the sipeimine evenly, the wet granulation is carried out, the granules are dried, 2g of micro silica gel powder is added, the mixture is mixed evenly, and the mixture is pressed into 1000 tablets, thus obtaining the tablets.

Example 4:

taking 25g of the sibiricin and 100g of the quercetin.

Firstly, adding 25g of the sipeimine into 38g of the starch, adding 2g of the micro silica gel powder, uniformly mixing, and filling into 1000 capsules.

Then 100g of quercetin is added with 30g of starch and mixed evenly, then 200g of starch is added and mixed evenly, then 2g of aerosil is added and mixed evenly, and the mixture is filled into 1000 capsules with different colors from the capsules containing the bevacizine.

The two capsules are taken 1 granule each time.

Example 5:

taking 25g of the sibiricin and 100g of the quercetin.

Firstly, adding 25g of the sibiricin into 38g of the starch, granulating by a wet method, drying granules, adding 2g of the micro silica gel powder, uniformly mixing, pressing into 1000 tablets and coating.

And then adding 30g of starch into 100g of quercetin, uniformly mixing, adding 200g of starch, uniformly mixing, granulating by a wet method, drying granules, adding 2g of superfine silica gel powder, uniformly mixing, pressing into 1000 tablets, and coating with a coating layer with a color different from that of the bevacizine tablets.

The two tablets are taken 1 granule each.

Example 6:

taking 25g of the sibiricin and 100g of the quercetin. Firstly, 100g of quercetin is added with 30g of dextrin and then is mixed with the sipeimine, then 2g of micro silica gel powder is added and mixed, and the mixture is filled into 1000 capsules, thus obtaining the capsules.

Example 7:

taking 25g of the sibiricin and 100g of the quercetin. Firstly, 100g of quercetin is added with 130g of dextrin and then mixed with the siberian, wet granulation is carried out, granules are dried, 2g of micro silica gel is added, mixed evenly and pressed into 1000 tablets, thus obtaining the tablet.

Example 8:

taking 25g of the sibiricin and 100g of the quercetin.

Firstly, adding 38g of dextrin and 2g of superfine silica gel powder into 25g of the sipeimine, uniformly mixing, and filling into 1000 capsules.

Then 100g of quercetin is added with 30g of dextrin and mixed evenly, then 200g of dextrin is added and mixed evenly, then 2g of aerosil is added and mixed evenly, and the mixture is filled into 1000 capsules with different colors from the capsules containing the bevacizine.

The two capsules are taken 1 granule each time.

Example 9:

taking 25g of the sibiricin and 100g of the quercetin.

Firstly, adding 38g of dextrin into 25g of the siberian, granulating by a wet method, drying granules, adding 2g of superfine silica gel powder, uniformly mixing, pressing into 1000 tablets and coating.

And then 100g of quercetin is added with 30g of dextrin and mixed evenly, then 200g of dextrin is added and mixed evenly, wet granulation is carried out, the granules are dried, 2g of superfine silica gel powder is added and mixed evenly, 1000 tablets are pressed and coated with coating layers with different colors from the bevacizin tablets.

The two tablets are taken 1 granule each time.

Example 10:

taking 25g of the sibiricin and 100g of the quercetin.

Taking quercetin, adding 80g of hydroxypropyl methylcellulose which is crushed and sieved by a 60-mesh sieve and 40g of cane sugar, weighing 110g of dextrin, uniformly mixing, preparing a soft material by using a 95% ethanol solution as an adhesive, sieving by a 20-mesh sieve, granulating, drying, grading by a 20-mesh sieve, adding 1% of magnesium stearate into dried granules, uniformly mixing, tabletting, wherein each tablet is 0.33g, and coating to obtain the sustained-release tablet, wherein a dissolution test shows that the sustained-release tablet is slowly released within 24 hours.

Taking 25g of the siberian, adding 38g of starch, preparing a soft material by taking water as an adhesive, sieving with a 20-mesh sieve, granulating, drying, grading with the 20-mesh sieve, adding 1% of magnesium stearate into the dried granules, uniformly mixing, tabletting, coating with hydroxypropyl methyl cellulose, and then coating with sugar to obtain the tablet, wherein a dissolution test shows that the tablet is released suddenly after 1 hour.

The two tablets are taken 1 granule each time.

Example 11:

taking 25g of the sibiricin and 100g of the quercetin.

Taking 25g of the sipeimine, adding 38g of starch, using water as a binding agent to prepare a soft material, sieving with a 20-mesh sieve for granulation, drying, granulating with the 20-mesh sieve, adding 1% of magnesium stearate into the dried granules, uniformly mixing, tabletting, wherein each tablet is 0.33g, and the dissolution test shows that the tablet can be released suddenly after 1 hour.

Filling two tablets into the same capsule to obtain the sustained-release micro-tablet capsule.

Example 12:

taking 25g of the sibiricin and 100g of the quercetin.

Taking 100g of quercetin, adding 80g of hydroxypropyl methylcellulose which is crushed and sieved by a 60-mesh sieve and 40g of cane sugar, then weighing 110g of dextrin, uniformly mixing, and preparing the mixture into microspheres by a fluidized bed packaging method, wherein dissolution tests show that the microspheres are slowly released within 24 hours.

Taking 25g of the sipeimine, adding 38g of starch, using water as a bonding agent to prepare a soft material, sieving with a 20-mesh sieve for granulation, drying, grading with the 20-mesh sieve, and preparing into microspheres, wherein a dissolution test shows that the sipeimine is released suddenly after 1 hour.

Mixing the two microspheres uniformly and filling the mixture into the same capsule to obtain the sustained and controlled release microsphere capsule.

Example 13

Taking 25g of the sibiricin and 100g of the quercetin.

The two kinds of microspheres are respectively filled into different capsules, and one capsule is taken when the two kinds of microspheres are taken respectively.

Example 10:

inhibition of citric acid-induced cough in guinea pigs

1. Material

1.1 qualified Hartley guinea pig of experimental animal, the weight is 250-300 g, and the male and female are half each, provided by Guangdong province medical experimental animal center.

1.2 drugs and reagents codeine phosphate; a sibiricin; quercetin; the composition is prepared by combining the sibiricin and the quercetin according to the weight ratio of 25: 100.

1.3 apparatus YLS-8A cough-inducing asthma apparatus (product of Shandong province medical science apparatus station).

2. Method of producing a composite material

Taking 50 qualified Hartley guinea pigs, weighing 250-300 g, randomly dividing into 5 groups of blank control group, codeine phosphate group, Sibemectin group, quercetin group and Sibemectin and quercetin composition group, and each group comprises 10 animals. The guinea pigs of each group were gavaged at a dose of 0.5ml/100g body weight according to the following table 1, wherein a blank control group was given an equal volume of physiological saline, and after 1 hour of the gavage, the citric acid spray was started for 6 minutes, and the spraying was terminated, and the number of coughs (typical coughs were crisp and loud, and often had a first pounding action) within 10 minutes from the start of spraying was observed and recorded.

3. Results

As can be seen from table 1, the codeine phosphate group has good antitussive effect, and has significant difference (p <0.01) compared with the blank control group; the combination group of the siberian extract and the quercetin also has good antitussive effect, and has significant difference (p is less than 0.01) compared with a blank control group; the sibericin group has certain cough relieving drug effect, and has statistical difference (p is less than 0.05) compared with a blank control group; the quercetin group and the blank control group have no difference statistically; compared with a single-dose combination of the sibericin and the quercetin, the combination of the sibericin and the quercetin has better cough relieving effect and difference in statistics (p is less than 0.05).

The above results demonstrate that: the combination of the siberian and the quercetin has good antitussive effect, and is superior to the single administration group of the siberian, and the quercetin has no antitussive effect.

TABLE 1 inhibition of citric acid-induced cough in guinea pigs by the test drugs (n ═ 10)

Group of	Administration of drugsDosage form	Number of coughs
			Blank control	Physiological saline	32.3±9.56
Codeine phosphate	7ml/kg	14.8±6.29^**
			Siberine	15mg/kg	22.5±7.90^*
Quercetin	60mg/kg	31.7±10.2
			Pharmaceutical combination of sibiricin and quercetin	15mg/kg+60mg/kg	13.6±5.23^**#

Note: "^*"P <0.05 compared to placebo; "^**"P <0.01 compared to blank control"^#"; compared with the element group, P is less than 0.05.

Example 11: influence on mouse phenol Red excretion experiment

1. Material

1.1 Experimental animal Kunming mouse, each half of male and female, the weight of which is 30-40 g, is provided by the medical experimental animal center of Guangdong province.

1.2 drugs and reagents ambroxol; a sibiricin; quercetin; the composition is prepared by combining the sibiricin and the quercetin according to the weight ratio of 25: 100.

1.3 Hitachi 3010 ultraviolet-visible spectrophotometer.

2. Method of producing a composite material

The Kunming mice are divided into 5 groups of blank control group, ambroxol group, sibiricin group, quercetin group, and quercetin composition group, and each group contains 10 mice. Following the dose of table 2 below, 0.2ml/10g was administered by continuous gavage for 2 days, 5% phenol red physiological saline 0.2ml/10g was intraperitoneally injected 30 minutes after the last administration, the mice were sacrificed and the trachea was separated after 30 minutes, a section of the trachea from the thyroid cartilage to the trachea branch was cut off, placed in a test tube containing 3ml of physiological saline, 0.1ml of 15% sodium bicarbonate solution was added, centrifuged, and the supernatant was taken and the OD was measured at 546 nln. And (5) converting the phenol red content according to a phenol red standard curve. Standard curve: phenol red standard solutions were prepared at 0.1. mu.g/ml, 0.3. mu.g/ml, 0.5. mu.g/ml, 0.7. mu.g/ml, l. mu.g/ml, 3. mu.g/ml, 5. mu.g/ml and 10. mu.g/ml, respectively. If the medicine can increase the secretion function of the respiratory tract, the excretion amount of phenol red can be increased, so the content of the phenol red can be measured, and the difference of the phlegm-discharging effect of the medicine can be compared.

3. Results

As can be seen from Table 2, compared with the blank group, the expectorant ambroxol can significantly improve (P <0.01) the excretion amount of phenol red in mice, and has statistical differences, which indicates that ambroxol has good expectorant effect; the excretion amount of the phenol red of the mouse with the combination of the sipeimine and the quercetin is obviously improved (P is less than 0.01) compared with that of a blank group, and the statistical difference is obtained; the quercetin group and the blank control group have no difference statistically; the excretion amount of the phenol red of the mouse with the combination of the sipeimine and the quercetin is higher than that of the mouse with the independent administration group of the sipeimine (P <0.05), and the statistical difference is obtained.

The above results demonstrate that: the combination of the sipeimine and the quercetin has good phlegm eliminating effect, the phlegm eliminating effect is superior to that of a single administration group of the sipeimine, and the quercetin has no phlegm eliminating effect.

Table 2 effect of test drugs on mouse phenol red excretion experiments (n ═ 10)

Composition	Dosage form	Phenol Red concentration (ug/ml)
			Blank control	Physiological saline	0.79±0.34
Ambroxol	24mg/kg	2.83±0.75^**
			Siberine	25mg/kg	1.57±0.83^*
Quercetin	100mg/kg	0.86±0.31
			Combination of sibericin and quercetin	25mg/kg+100mg/kg	2.72±0.53^**#

Note: "^*"P <0.05 compared to placebo; "^**"P <0.01 compared to placebo; "^#"compared with the group of the sibiricin, P is less than 0.05.

Example 12: asthma relieving action of acetylcholine histamine induced asthma in guinea pig

1. Material

1.2 drugs and reagent aminophylline; a sibiricin; quercetin; the composition is prepared by combining the sibiricin and the quercetin according to the weight ratio of 25: 100.

2. Method of producing a composite material

The method comprises the steps of firstly preselecting the incubation period of inducing asthma of the guinea pig, buckling the guinea pig on a YLS-8A asthma-inducing instrument, adjusting the air speed and the atomizing amount of an ultrasonic atomizer and the caliber of a spray head according to parameters set by a preset experiment, spraying mixed liquid atomizing air of 2% of acetylcholine chloride and 0.1% of histamine phosphate at a constant speed for 15 seconds, observing and recording the incubation period of inducing asthma of the guinea pig from the beginning of spraying to the onset of asthma, wherein the guinea pig has obvious shortness and difficulty in breathing, cyanosis around the mouth, abdominal muscles rapidly and greatly contract and relax along with breathing, the head shakes along with the breathing frequency, restlessness, teetering gait and convulsion falling, namely the onset of asthma. The guinea pigs were quickly moved to good ventilation, supplemented with artificial respiration if necessary. Guinea pigs with a latency of less than 100 seconds were selected for the official experiments and this latency was taken as the pre-dose latency. The screened sensitive guinea pigs were randomly divided into 5 groups of 10 animals each. The drug dilution concentration is the same as that of guinea pig citric acid cough-inducing experiment. Each group was gavaged at 20mL/kg 2 times a day for 2 days continuously, and after 1 hour of the last administration, the asthma-inducing latency of each guinea pig was determined under the same conditions (if no wheezing attack occurred within 6 minutes after administration to the guinea pig, the asthma-inducing latency of the guinea pig was calculated as 6 minutes). The incubation period of asthma induction in guinea pigs of each experimental group was examined by t-test between groups.

3. Results

As can be seen from Table 3, the combination of the antiasthmatic aminophylline, the cebemectin and the quercetin can remarkably prolong the asthma-inducing incubation period (P is less than 0.01) of the acetylcholine histamine asthma-inducing guinea pig compared with the blank group, and the statistical differences show that the combination of the aminophylline, the cebemectin and the quercetin has good antiasthmatic effect; compared with the blank group, the sibericin can prolong the asthma-inducing latent period (P is less than 0.05) of the acetylcholine histamine asthma-inducing guinea pig, has statistical difference, and has certain asthma-inducing effect; the quercetin group has no statistical difference compared with the blank group, which indicates that the quercetin has no obvious asthma relieving effect; compared with a group which singly administers the sipeimine, the combination of the sipeimine and the quercetin remarkably prolongs the asthma incubation period (P is less than 0.05), and has difference in statistics.

The above results demonstrate that: the combination of the sipeimine and the quercetin has good antiasthmatic effect, the antiasthmatic effect is superior to that of a single administration group of the sipeimine, and the quercetin has no obvious antiasthmatic effect.

TABLE 3 Effect of the tested drugs on the incubation period of asthma induced in Guinea pigs (n ═ 10)

Example 13

Synergistic effect of quercetin on sibericin cough relieving

1. Material

1.1 Experimental animals SPF grade male Kunming mice, weighing 18-22 g, were provided by the Guangdong province medical laboratory animal center.

2. Method of producing a composite material

Animals were randomly divided into 16 groups including a blank control group, a sibiricin 5 dose group, a quercetin 5 dose group, and a sibiricin + quercetin 5 dose group, each group containing 10 animals, and the doses are shown in table 4. The experiment was started 2 days after animal feeding. The corresponding drugs were administered to each group by intragastric administration at the doses shown in Table 4, and after 1 hour of administration, the drugs were sequentially placed in WBP whole body plethysmography detection system of BUXCO corporation and sprayed with ammonia. Adding 25% concentrated ammonia water into the atomizing cup, atomizing for 15 seconds, and recording the cough frequency within 3 minutes.

The number of coughs in each group is expressed as mean ± SD, and variance analysis is performed by using SPSS16.0 statistical software, and differences between groups are compared, and differences are significant when P is less than 0.05.

The results were analyzed using the Calcusyn software (Biosoft, USA) accepted for interaction studies, and the effect-Combination Index (CI) was calculated by plotting the effect-combination index curve of the antitussive rate. If the CI value is equal to 1, the type of interaction of the two drugs is simply additive; if the CI value is less than 1, the interaction form of the two medicines is synergy; if the CI value is greater than 1, the type of interaction between the two drugs is antagonistic.

3. Results

The number of coughs and statistical analysis of the animals in each group are shown in table 3.

The cough frequency is converted into the cough relieving rate, the cough relieving rate is used as a drug effect index, Calcusyn statistical software is applied, and an effect-combination index curve of the bevacizin and the quercetin is drawn (see figure 1). When the combination of the bemectin and the quercetin is used, the CI values calculated by 5 dose points of the compound are all less than 1, the interaction types are all expressed as synergy, and the smaller the effect value is, the stronger the synergy is, and the regularity is realized.

Table 3 dose and number of coughs administered to each group (n ═ 10)

Note: compared with the blank control group, the composition of the composition,^*P<0.05，^**P<0.01

the technical features of the embodiments described above may be arbitrarily combined, and for the sake of brevity, all possible combinations of the technical features in the embodiments described above are not described, but should be considered as being within the scope of the present specification as long as there is no contradiction between the combinations of the technical features.

The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.

Claims

1. A pharmaceutical composition for relieving cough, eliminating phlegm and relieving asthma is characterized in that the active ingredients comprise bemisin and quercetin; the mass and dosage ratio of the sipeimine to the quercetin is as follows: 5-50: 20 to 200 parts.

2. The pharmaceutical composition for relieving cough, eliminating phlegm and relieving asthma according to claim 1, wherein the mass ratio of the behcet and the quercetin is as follows: 25 +/-2: 100 +/-2.

3. The pharmaceutical composition for relieving cough, eliminating phlegm and relieving asthma according to claim 2, wherein the mass ratio of the behcet and the quercetin is as follows: 25: 100.

4. use of a pharmaceutical composition according to any one of claims 1 to 3 for the preparation of a pharmaceutical preparation for relieving cough, eliminating phlegm and relieving asthma.

5. A pharmaceutical preparation for relieving cough, eliminating phlegm and relieving asthma, which is characterized by comprising the pharmaceutical composition for relieving cough, eliminating phlegm and relieving asthma according to any one of claims 1 to 3 and pharmaceutically acceptable auxiliary materials.

6. The pharmaceutical preparation according to claim 5, wherein the pharmaceutical preparation is in the form of tablets, capsules, granules, pills, or microspheres.

7. Pharmaceutical formulation according to claim 5 or 6, characterized in that said pharmaceutically acceptable adjuvants are selected from: one or more of starch, lactose, mannitol, calcium hydrogen phosphate, dextrin, polyvinylpyrrolidone, cellulose and its derivatives, and polyethylene glycol.

8. Pharmaceutical formulation according to claim 5 or 6, characterized in that said pharmaceutically acceptable excipients are selected from chitosan.

9. The pharmaceutical formulation of claim 7, wherein the starch is selected from the group consisting of: carboxymethyl starch, tapioca starch, soluble starch, or pregelatinized starch;

the cellulose is selected from: methylcellulose, ethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, or microcrystalline cellulose.

10. The pharmaceutical preparation according to claim 7, wherein the polyethylene glycol is polyethylene glycol 200-20000.

11. The pharmaceutical formulation of claim 7, wherein the pharmaceutical formulation is in the form of a capsule.